BirchBioMed Inc.
Hervé Girsault is an accomplished executive with extensive experience in the biopharmaceutical and healthcare sectors. Currently serving as Chief Business Officer at BirchBioMed Inc. since March 2023, Girsault is focused on developing novel treatments for organ fibrosis. As Co-founder and Managing Partner of CHG BioVenture SA since 2005, Girsault provides C-Suite advisory services to biotech and medtech companies. Previous roles include Acting Head of Business Development & Licensing at NLS Pharmaceutics AG, President and CEO at Synarc, and Global Head of M&A and Business Development at Novartis. Girsault also held the position of General Manager at Nestlé Nutrition North America (Gerber) and began a career in management consulting with PwC. Girsault earned an MBA in Finance and Corporate Strategy from Columbia Business School.
This person is not in any teams
This person is not in any offices
BirchBioMed Inc.
BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation. A University of British Columbia (“UBC”) spin-off, BirchBioMed holds the exclusive, worldwide pharmaceutical license from UBC for two medical therapeutic technologies that mark significant medical breakthroughs in the treatment of fibrosis and certain autoimmune diseases. Initially funded by key strategic donors and government bodies, including the Canadian Institute of Health Research and the Natural Sciences and Engineering Research Council of Canada (the Canadian counterpart of the U.S. National Institutes of Health), BirchBioMed's licensed technology has secured more than $6 million in government and association grants, coupled with additional university resources. It is also the first technology that UBC has advanced from discovery through Phase I clinical trials with support strictly from government/private donations.